The cell membrane-associated enzyme CD10/neutral endopeptidase 24.11 (CD10/NEP) functions in multiple organ systems to downregulate responses to peptide hormones. Recently, CD10/NEP was found to hydrolyze bombesin-like peptides (BLP), which are mitogens for normal bronchial epithelial cells and small cell lung carcinomas. Growth of BLP-responsive small cell lung carcinomas was potentiated by CD10/NEP inhibition, implicating CD10/NEP in regulation of BLP-mediated tumor growth. BLP are also likely to participate in normal lung development because high BLP levels are found in fetal lung, and bombesin induces proliferation and maturation of human fetal lung in organ cultures and murine fetal lung in utero. To explore potential roles for CD10/NEP in regulating peptide-mediated human fetal lung development, we have characterized temporal and cellular patterns of CD10/NEP expression and effects of CD10/NEP inhibition in organ cultures. Peak CD10/NEP transcript levels are identified at 11-13 wk gestation by Northern blots and localized to epithelial cells and mesenchyme of developing airways by in situ hybridization. CD10/NEP immunostaining is most intense in undifferentiated airway epithelium. In human fetal lung organ cultures, inhibition of CD10/NEP with either phosphoramidon or SCH32615 increases thymidine incorporation by 166-182% (P < 0.025). The specific BLP receptor antagonist, [Leu'3-psi(CH2NH)Leu 1'bombesin abolishes these effects on fetal lung growth, suggesting that CD10/NEP modulates BLP-mediated proliferation. CD10/NEP expression in the growing front ofairway epithelium and the effects ofCD10 / NEP inhibitors in lung explants implicate the enzyme in the regulation of peptide-mediated fetal lung growth. (J. Clin. Invest. 1992. 90:2517-2525.) Key words: bombesin * common acute lymphoblastic leukemia antigen * metalloendopeptidase * respiratory epithelium * growth regulation
Introduction
Molecular cloning and expression studies have shown that CD1O (common acute lymphoblastic leukemia antigen) is identical to the zinc metalloprotease, neutral endopeptidase 24.1 1 (NEP, "enkephalinase") (1) (2) (3) (4) . This cell membrane-associated enzyme (CDlO/NEP)' hydrolyzes a number of naturally occurring peptides, including the endogenous opioid pentapeptides Met-and Leu-enkephalin, substance P, neurotensin, oxytocin, bradykinin, angiotensins 1 and 2, atrial natriuretic factor, endothelin and the chemotactic peptide, f MLP (2, (4) (5) (6) . CDlO/NEP, which is expressed on early lymphoid progenitors, neutrophils, and a variety of nonhematopoietic cell types (5) (6) (7) (8) , functions in multiple organ systems to downregulate induced responses to peptide hormones (9) (10) (11) (12) (13) (14) (15) (16) . For instance, CD lO/NEP is expressed at high levels in the lung (17) (18) (19) , where it modulates responses to tachykinins such as substance P that mediate neurogenic inflammation (9) (10) (11) (12) 16 ). Inhibition of CD lO/NEP dramatically increases both the binding of substance P to bronchial membranes and the resulting proinflammatory physiological effects (9) (10) (11) 16 ).
An additional family of peptides whose effects are modulated by CDlO/NEP are the bombesin-like peptides (BLP) (20) . The amphibian peptide bombesin and its homologue gastrin-releasing peptide (GRP) are potent mitogens for normal bronchial epithelial cells (21) , fibroblasts (22) (23) (24) , and certain tumor types including small cell lung carcinomas (SCLCs) (25, 26) . In many SCLCs, an autocrine loop exists whereby tumor cells secrete BLP, express BLP receptors, and respond to BLP with increased cellular proliferation (25) . CD10/NEP inactivates BLP by cleaving these peptides at two sites within the 7 amino acid (aa) conserved carboxy terminus that is required for biologic activity (27) . The growth of BLPresponsive SCLCs was inhibited by CD1O/NEP and potentiated by CD10/NEP inhibition, implicating the enzyme in the regulation of BLP-mediated autocrine tumor cell growth (27) .
BLP have also been implicated in normal fetal lung development (28, 29) . GRP mRNAs were first detected in human fetal lung at 9-10 wk gestation, peaked at 16-30 wk at levels 25-fold higher than in adult lungs, and subsequently declined to near adult levels by 34 wk gestation (28) . In situ hybridization analyses of GRP mRNAs in human fetal lung revealed a proximalto-distal spatial and temporal pattern ofgene expression, apparently in parallel with the growth of the airways (28) . The high levels of GRP mRNAs found during the pseudoglandular and canalicular phases of pulmonary development suggested that BLP might play an important role in this process. This hypothesis was subsequently confirmed in human and murine fetal lung organ culture studies (29) . Bombesin was added to human and murine fetal lung organ cultures and administered to pregnant mice during the respective time periods in gestation when endogenous fetal lung GRP levels were most elevated (29) . Bombesin administration resulted in a dose-dependent increase in fetal lung growth and maturation as assessed by biochemical and morphological approaches (29) . In addition, an antibombesin (BN) (mAb) blocked murine fetal lung maturation in vivo (30) and in serum-free lung organ cultures (29) .
Recently CD10/NEP immunoreactivity has been identified in epithelial cells of both fetal and adult lung ( 17, 27) . Since CD10/NEP modulates BLP effects and BLPs stimulate the growth and maturation of fetal lung, we have analyzed the temporal and cellular expression ofCDO0/NEP in human fetal lung and compared it to that of BLP. We have also assessed the potential role ofCDI0/NEP in fetal lung development by evaluating the proliferation of human fetal lung in organ cultures treated with specific CDI0/NEP inhibitors.
Methods
Fetal tissue collection. Human fetal lung tissues were obtained within 1 h after elective therapeutic abortions up to - Immunoperoxidase analyses. Immunoperoxidase analyses were performed with serial sections ofthe same fetal lungs that were used for in situ hybridization. The human CDIO monoclonal antibody (mAb) J5 (a gift from Jerome Ritz, Dana-Farber Cancer Institute, Boston, MA) was used as previously described (27) . The affinity-purified IgG fraction of polyclonal rabbit anti-NEP (a gift from Catherine Lucas at Genentech, Inc., San Francisco, CA) was used at a working dilution of 1:2,000. mAb to cytokeratins (CAM 5.2) (22) and normalized for DNA content (cpm/Mg DNA). DNA content was determined after trichloroacetic acid precipitation by the method of Burton (41) . Duplicate or quadruplicate samples were obtained for each culture condition in each of three independent experiments. The thymidine incorporation in untreated control samples from each experiment (mean±SE) was defined as baseline and the percentage change in thymidine incorporation in each of the treated samples determined (mean±SE). The results from the three independent experiments were pooled for final analysis.
Results
Northern analyses. To analyze CD10/NEP transcripts during fetal lung development and compare the temporal expression of CD10/NEP to that of the mammalian BLP, GRP, total RNAs from fetal lung samples ( 10-22 wk gestation) were prepared, blotted, and probed with both a GRP cRNA and CD 10/ NEP cDNA. GRP transcripts (-900-950 bp) were first detectable at 10-12 wk and subsequently increased and peaked between 15-20 wk gestation ( Fig. 1 A and [28] ). In contrast, the major 5.7-and 3.7-kb CD10/NEP transcripts (1, 2, 13) were barely detectable at 10 wk gestation, peaked at 1 1-12 wk, and declined thereafter such that they were below the limits of detection on Northern blots of total RNA at 16 wk (Fig. 1 B) .
GRP and CD1O/NEP transcripts were subsequently quantitated by densitometry and normalized for the relative amounts of total RNA by scanning the negative of the photograph from the corresponding ethidium bromide stained gel (Fig. 1 C) . The normalized densitometric analysis indicates that CD1O/NEP transcripts peaked in fetal lung during the first trimester and subsequently declined at about the same time ( 14-15 wk, early second trimester) that GRP transcript levels rose (Fig. 1 D) .
In situ hybridization. In situ hybridization was subsequently performed to specifically determine which cells in human fetal lung transcribed CD1O/NEP (Fig. 2) . Fetal lung sections were examined by light microscopy to characterize cellular morphology (Fig. 2, a, c, e, and g ) and by dark-field microscopy to visualize autoradiographic signals better (Fig. 2,  b, d, f and h ). CD10/NEP transcripts were detectable as early as 8 wk gestation (Fig. 2, a and b) . The strongest hybridization signals were observed in the most primitive distal airways where the majority of grains overlay epithelial cells (Fig. 2, a  and b) . However, there was also increased grain density overlying airway-associated mesenchyme and weak hybridization associated with scattered mesenchymal cells in the loose connective tissue in between airways (Fig. 2, a and b) . To confirm the specificity of the CD10/NEP hybridization signals, additional 8-wk fetal lung sections were hybridized with the corresponding CD10/NEP sense probe which is identical, ratherthan complementary, to CD10/NEP transcripts. As shown in Fig. 2 By 12 wk gestation, CD10/NEP transcripts were easily detectable in the epithelial cells and airway-associated mesenchyme of distal less differentiated airways (Fig. 2, e and f) . There was a trend towards stronger CD10/NEP hybridization in distal as compared to proximal airways (data not shown) whereas GRP transcripts were only detectable in more differentiated proximal airways that had begun to branch (data not shown and [28 ] ).
At 15 wk (Fig. 2, g and h) and more weakly at 17 wk gestation (data not shown), CD10/NEP transcripts were predominantly associated with the distal most undifferentiated airways. ."-Nna! ization studies. Initially, immunoperoxidase studies were done on paraformaldehyde-fixed/cryostat (PF/C) sections with reagents including anti-CD10/NEP, cytokeratin, and desmin monoclonal antibodies. Consistent with the previous in situ studies, there was CD10/NEP immunostaining ofboth the epithelium and airway-associated mesenchymal tissue at 8 wk gestation (Fig. 3 a) . The specificity of CD10/NEP immunostaining was confirmed by demonstrating that serial sections incubated with CD10/NEP mAb that had been preabsorbed with soluble CD10/NEP had markedly reduced signals (Fig. 3 b) . To compare the localization of CD10/NEP to that of other known markers, additional serial sections were stained with anticytokeratin and antidesmin mAbs. Cytokeratin immunostaining of the same 8-wk fetal lung identifies airway epithelium in proximal (P) and distal (D) airways (Fig. 3 c) , whereas desmin immunostaining identifies smooth muscle differentiation which is associated with only the more differentiated proximal airways (Fig. 3 d) . Comparisons between Fig. 3 , a, c, and d, demonstrate that proximal more differentiated airways have weaker CD10/NEP immunostaining than distal less differentiated airways.
In 12-wk PF/C sections, there was only weak CD10/NEP antigen-specific immunostaining of proximal airway epithelium, with weak to moderate staining of distal airways (Fig. 3  e) . Both the epithelial cells which were identified by cytokeratin immunostaining and the mesenchyme surrounding desmin-positive differentiated smooth muscle cells expressed CD 10/NEP (Fig. 3 g ). The specificity ofCD 10/ NEP immunostaining at 12 wk was confirmed by incubating additional fetal lung sections with the CD1O/NEP mAb following preabsorption with soluble CD10/NEP (Fig. 3f) .
Since previous studies suggested that there might be differences between the CD1O/NEP immunostaining of PF/C sections and paraformaldehyde-fixed/paraffin-embedded (PF/ PE) sections (27) , we also evaluated PF/PE fetal lung samples for CD10/NEP expression (Fig. 4) . Both the anti-CD10 mAb (Fig. 4, A-J) and an anti-CD10 antiserum (data not shown) gave similar patterns of CDlO/NEP immunostaining. In the PF/PE sections the epithelial CD10/NEP staining was particularly prominent whereas the mesenchymal staining was less pronounced (Fig. 4) . These results suggest that the method of tissue processing may affect CD10/NEP immunoreactivity in specific tissues (42) (43) (44) . Consistent with our results from the Northern analysis (Fig. 1) , in situ hybridization (Fig. 2) and immunostaining of PF/C sections (Fig. 3) , CD1O/NEP expression in PF/PE sections was most intense at earlier time points (12 wk, Fig. 4, A and B) . In later samples (15-18 wk), CD10/NEP expression was primarily restricted to keratin-positive epithelial cells in the less differentiated distal airways not yet surrounded by desmin-positive mesenchymal cells (Fig. 4,  C-F, and data not shown) . Additional PF/PE-fixed samples incubated with CD10/NEP mAb or antiserum that had been preabsorbed with soluble CD10/NEP had markedly reduced signals, confirming the specificity ofthe immunostaining (Fig.  4, B, D, and F, and data not shown) .
In previous studies using adult animals, inhibition of CD1O/NEP potentiated the bronchoconstriction associated with substance P release (9) (10) (11) 16 ). Since substance P is released from nerve fibers localized to the desmin-positive mesenchymal cells surrounding proximal airways, we examined more mature fetal lung specimens for additional CD10/NEP mesenchymal immunostaining. PF/C fetal lung sections were used because mesenchymal CD10/NEP immunostaining was more prominent with this method offixation (Fig. 3 versus Fig.  4 ). The CD10/ NEP and desmin immunostaining ofserial sections from a 22-wk fetal lung is shown in Fig. 5 . Whereas the CDIO/NEP immunostaining of airway-associated mesenchyme in younger fetal lungs was external to and distinct from desmin-positive smooth muscle cells (Figs. 3 and 4) , the CD I0/NEP immunostaining in the older fetal lungs included desmin-positive smooth muscle cells surrounding the proximal airways (Fig. 5) , as well as bronchial-associated glands (data not shown).
Human fetal lung organ cultures. To explore the potential function of CD1O/NEP in developing lung, fetal lung organ cultures were set up as previously described (29) using three different 14-15-wk gestation human fetal lungs. The 14-15-wk timepoint was chosen because both CD10/NEP and GRP are clearly detectable in human fetal lung during this interval (Fig.  1) . Fetal lung organ cultures were incubated with media alone (Neg), bombesin (BN), the specific bombesin receptor antagonist Ll 3BN, BN plus Ll 3BN, the specific CD10/NEP inhibitor SCH32615 (38) , SCH32615 plus L13BN, or an unrelated CD1O/NEP inhibitor, phosphoramidon (27) . Samples were subsequently evaluated for [3H]thymidine incorporation which was normalized for DNA content (Methods, [29] ).
[3H]thymidine incorporation in samples incubated with media alone was compared to [3H]thymidine incorporation in samples incubated with bombesin, LI 3BN, SCH32615, phosphoramidon, or the respective combinations and the percent- age change in thymidine incorporation resulting from the additions determined. The results from the three independent experiments are pooled and summarized in Fig. 6 . Bombesin significantly increased thymidine incorporation in the fetal lung organ cultures ( 1 16% increase, P < 0.001 ) and the addition of LI 3BN to bombesin-treated cultures reduced [3H Hthymidine incorporation to baseline levels. The CD1O/NEP inhibitor SCH326 15 also significantly increased thymidine incorporation in fetal lung organ cultures (166% increase, P < 0.001). The addition of L1 3BN to SCH326 15-treated cultures similarly reduced thymidine incorporation to baseline levels suggesting that the SCH32615 effect was mediated by BLPs. To obtain additional evidence that the increased thymidine incorporation in SCH32615-treated fetal lung samples was a specific consequence of CD1O/NEP inhibition, additional samples were treated with an unrelated CD10/NEP inhibitor, phosphoramidon. As shown in Fig. 6 , phosphoramidon-treated fetal lung organ cultures also incorporated significantly more [3H]thymidine ( 182% increase, P < 0.025).
Discussion
We have evaluated the expression and function ofCD 10/ NEP in human fetal lung because the enzyme regulates BLP-mediated growth of SCLC and BLPs stimulate the proliferation and maturation ofhuman and murine fetal lung organ cultures (29) and normal pulmonary neuroendocrine cells (45) . By in situ hybridization analysis, CD10/NEP transcripts were identified in epithelial cells, airway-associated mesenchyme, and scattered mesenchymal cells as early as 8 wk gestation. The pattern ofCD I0/NEP immunoreactivity was similar to that of the corresponding transcripts, with prominent epithelial staining primarily of distal undifferentiated airways. Consistent with Northern analyses, CD1O/NEP immunostaining was most prominent in the first trimester and declined thereafter. Given the tight correlation between CD10/NEP mRNA levels, cell surface expression and enzymatic activity ( 1, 2) , these results are predictive for high levels of cell surface CD10/NEP enzymatic activity in the least differentiated airways in early fetal lung development. Therefore, the observation that human fetal lung proliferation is increased when CD O0/NEP is inhibited with either SCH326 15 or phosphoramidon is of particular interest. The fact that a bombesin receptor antagonist abolishes the effects of CD10/NEP inhibitors on human fetal lung suggests that CD10/NEP is regulating local levels of endogenous BLPs and that the enzyme may function to limit BLP effects during the earliest stages of fetal lung development. CDJO/Neutral Endopeptidase 24.11 in Human Fetal Lung 2523 differentiated airways is of interest because CD10/NEP is also expressed by immature progenitors of another cellular lineage. CDlO was originally identified as a cell surface glycoprotein on normal and malignant lymphoid progenitors that were either uncommitted or committed to only the earliest stages ofB or T cell differentiation (reviewed in reference 8). CD10-positive lymphoid progenitors are abundant early in fetal hematopoietic development but decline in number with subsequent fetal maturation and birth (8) . Recent studies indicate that CD 10/ NEP also modulates the growth of lymphoid progenitors raising the possibility that the enzyme may function in a similar capacity in different organs (47) . Since CD 10/ NEP is predominantly expressed by early lymphoid progenitors in fetal bone marrow and liver and by undifferentiated epithelial cells in fetal lung, there may be common regulatory elements controlling expression of the enzyme in different tissues during fetal development. Of note, several 5' alternatively spliced CD 10/ NEP untranslated region cDNA sequences have been identified, raising the possibility that unique regulatory elements control CD1O/NEP expression at different developmental stages or in different cell types (3) . CD10/NEP may have different roles in early and late stages of pulmonary development, depending upon the specific cell types expressing the enzyme (16-19) and the localization of relevant CD10/NEP peptide substrates. For this reason, the CDI0/NEP immunostaining ofdesmin positive mesenchymal cells surrounding proximal airways in older fetal lungs is also of interest. CD10/NEP has previously been identified on cultured fibroblasts (8) and multiple tumors of mesenchymal origin (48) . The enzyme may also modulate peptide-mediated proliferation of pulmonary mesenchymal cells since BLPs are known mitogens for pulmonary fibroblasts (24, 29) . Since additional pulmonary peptides such as substance P and endothelin are also CD10/NEP substrates and fibroblast mitogens (49, 50) , the enzyme may regulate fibroblast proliferation mediated by multiple pulmonary peptides. CD10/NEP is also known to modulate substance P-mediated bronchoconstriction in adult animal models (9) (10) (11) 16) . Substance P, which is released by nerve fibers located in mesenchyme surrounding proximal airways, presumably acts on CD10/ NEP positive smooth muscle elements.
Our results indicate that CD10/NEP is primarily expressed by undifferentiated bronchial epithelium in developing airways and that the enzyme modulates the growth ofhuman fetal lung. These studies provide additional insight into the role of the enzyme in regulating pulmonary peptide-mediated proliferative responses.
